A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC)
Inclusion Criteria:
Each patient must meet all of the following inclusion criteria:
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
Piitsburgh, Pennsylvania, United States
Bairro Nazare - Salvador, Brazil
Barretos/sp, Brazil
Fortaleza/ce, Brazil
Lajeado - Rs, Brazil
Piracicaba - Sp, Brazil
Porto Alegre- Rs, Brazil
Porto Alegre/rs, Brazil
Ribeirao Preto - Sp, Brazil
Rio de Janeiro Rj, Brazil
Sorocaba - Sp, Brazil
Heraklion Crete, Greece
Hokkaido, Japan
Kita-gun, Japan
Shimizucho Sunto-gun, Japan
Suntou-gun, Japan
Durango Durango, Mexico
Mexico City Distrito Federal, Mexico
Zapopan Jalisco, Mexico
Liepaja, Portugal